Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 1
1991 1
1997 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 1
2014 1
2016 2
2017 2
2018 3
2019 1
2020 5
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu QS, Batist G, Hughes ME, Kremer JD, Garraway LA, Winer EP, Tolaney SM, Lin NU, Buchanan SG, Wagle N. Wander SA, et al. Among authors: oakley gj. Cancer Discov. 2020 Aug;10(8):1174-1193. doi: 10.1158/2159-8290.CD-19-1390. Epub 2020 May 13. Cancer Discov. 2020. PMID: 32404308 Free PMC article. Clinical Trial.
Olaratumab-induced Biomarker Modulation in Sarcomas-Response.
Martín-Broto J, Peterson PM, Oakley GJ, Ceccarelli M, Jones RL. Martín-Broto J, et al. Among authors: oakley gj. Mol Cancer Ther. 2021 Oct;20(10):2094. doi: 10.1158/1535-7163.MCT-21-0497. Mol Cancer Ther. 2021. PMID: 34607902 No abstract available.
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Borthakur G, Martinelli G, Raffoux E, Chevallier P, Chromik J, Lithio A, Smith CL, Yuen E, Oakley GJ 3rd, Benhadji KA, DeAngelo DJ. Borthakur G, et al. Among authors: oakley gj 3rd. Cancer. 2021 Feb 1;127(3):372-380. doi: 10.1002/cncr.33188. Epub 2020 Oct 27. Cancer. 2021. PMID: 33107983 Free article. Clinical Trial.
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
Martín-Broto J, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ 3rd, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. Martín-Broto J, et al. Among authors: oakley gj 3rd. Mol Cancer Ther. 2021 Jan;20(1):132-141. doi: 10.1158/1535-7163.MCT-20-0441. Epub 2020 Nov 11. Mol Cancer Ther. 2021. PMID: 33177152 Free article. Clinical Trial.
HER-2 amplification in tubular carcinoma of the breast.
Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW. Oakley GJ 3rd, et al. Am J Clin Pathol. 2006 Jul;126(1):55-8. doi: 10.1309/E0YE-KHBP-3YYQ-YUBD. Am J Clin Pathol. 2006. PMID: 16753605
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C, Ricci F, Diener JT, Yuen E, Smith C, Oakley GJ 3rd, Benhadji KA, Massard C. Even C, et al. Among authors: oakley gj 3rd. Invest New Drugs. 2020 Apr;38(2):402-409. doi: 10.1007/s10637-019-00739-x. Epub 2019 Apr 6. Invest New Drugs. 2020. PMID: 30953269 Free PMC article. Clinical Trial.
26 results